Novavax: positive EMA opinion for Covid vaccine

(CercleFinance.com) - EMA has recommended granting a conditional marketing authorisation for Novavax's COVID-19 vaccine Nuvaxovid to prevent COVID-19 in people from 18 years of age.


Nuvaxovid is the fifth vaccine recommended in the EU for preventing COVID-19.

After a thorough evaluation, EMA's human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the EU criteria for efficacy, safety and quality.

Taken together, the results of the two studies show a vaccine efficacy for Nuvaxovid of around 90%. The original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta were the most common viral strains circulating when the studies were ongoing.

There is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron.

Copyright (c) 2021 CercleFinance.com. All rights reserved.